医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Outcomes of Presbia Microlens Surgeries in Korean Study Demonstrate Excellent Results

2016年08月11日 PM09:00
このエントリーをはてなブックマークに追加


 

DUBLIN

Presbia PLC (NASDAQ: LENS), an ophthalmic device company and leader in near-vision restoration, announced the 12-month results of the 14 Presbia Flexivue Microlens™ surgeries performed on South Korean patients by Dr. Lee Jong Ho, founder of the BalGeunSeSang (BGSS) Eye Clinic, one of the world’s most prestigious eye clinics. The results of the surgeries using the Presbia Flexivue Microlens, an optical lens implant and an innovative solution for treating the age-related loss of near-vision, were presented at a recent symposium held in Seoul, South Korea.

Dr. Lee stated in his presentation that his patients’ outcomes were excellent and the data highly consistent with prior clinical studies completed in Europe. In eyes treated with the Presbia Flexivue Microlens, subjects gained an average of 5 lines of near vision. This means a person who could barely read a newspaper sub-headline prior to surgery, can now read the small print on a prescription eye drop bottle without the use of reading glasses.

“We continue to see consistency in excellent results reported by surgeons and their patients around the globe using the Presbia Microlens as a first-line surgical treatment to near-vision loss,” said Todd Cooper, President and CEO of Presbia. “The results reported at the Korean Symposium will support the introduction of our commercial activities in Korea. We are excited about the commercial potential for the Microlens in Korea as Korea, at 28%, has the highest LASIK penetration in the world. Approximately 67,000 LASIK surgeries are performed annually in the country, and the presbyopia market is estimated at 1.6 times the size of the LASIK market.”

Forward-Looking Statements

This release contains “forward-looking statements” made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Information provided and statements contained in this press release that are not purely historical are forward-looking statements. Such forward-looking statements only speak as of the date of this press release and Presbia assumes no obligation to update the information included in this press release. Statements made in this press release that are forward-looking in nature may involve risks and uncertainties, including, but not limited to, the factors listed under “Risk Factors” in our annual report on Form 10-K and quarterly reports on Form 10-Q. Accordingly, readers are cautioned that any such forward-looking statements are not guarantees and are subject to certain risks, uncertainties and assumptions that are difficult to predict. Although Presbia believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. Unless otherwise required by law, Presbia also disclaims any obligation to update its view of any such risks or uncertainties or to announce publicly the result of any revisions to the forward-looking statements made in this press release.

About Presbia

Presbia PLC (NASDAQ:LENS) is an ophthalmic device company that has developed and is currently marketing the presbyopia-correcting Presbia Flexivue Microlens™, a miniature lens that is implanted in a corneal pocket created by a femtosecond laser. The Presbia Flexivue Microlens™ has received a CE mark for the European Economic Area, allowing the lens to be marketed in over 30 countries across Europe. A staged pivotal U.S. clinical trial for the Presbia Flexivue Microlens™ commenced in 2014.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160811005231/en/

CONTACT

Presbia PLC
Monica Yamada, 323-860-4903
monica@presbia.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • 武田薬品がALK陽性非小細胞肺がんでのALUNBRIGTM(ブリガチニブ)のピボタル第2相ALTA試験の最新データを発表
  • Shinkowa Pharmaceutical Co., Ltd., Distributor of the World’s First Supplements Containing β-Nicotinamide Mononucleotide (NMN), Has Begun World-Wide Distribution of the Special Products “NMN PURE 3000″ and “NMN PURE 1500″
  • Interim Analysis of Ignyta’s Entrectinib Suggests Potential Best-in-Class Profile as a First-Line Targeted Therapy in Patients With ROS1-Positive Non-Small Cell Lung Cancer
  • Spectrum Pharmaceuticals Highlights Poziotinib Data in Non-Small-Cell Lung Cancer (NSCLC) Presented at the 18th IASLC World Conference on Lung Cancer in Japan
  • 武田呈报ALUNBRIGTM (brigatinib)治疗ALK阳性非小细胞肺癌枢纽性2期ALTA试验的更新结果